OBJECTIVE: The purpose of this study was to evaluate the efficacy of acupressure at the P6 point for the in-patient treatment of severe nausea and vomiting in early pregnancy. STUDY DESIGN: This was a prospective single-blind randomized control trial that involved 80 patients with nausea and vomiting plus ketonuria before 14 weeks of gestation. RESULTS: There was no difference between length of stay, amount of medication, or fluid required between the acupressure and placebo groups, although acupressure reduced the number of patients who stayed > or =4 nights in the hospital. Acupressure was well tolerated and not associated with an increase in perinatal morbidity or death. CONCLUSION: The use of acupressure at the P6 point does not reduce the amount of antiemetic medication that is required, the requirement for intravenous fluid, and median duration of in-patient stay more than the use of placebo. A small reduction was seen in the number of women who required > or =4 days in the hospital.
RCT Entities:
OBJECTIVE: The purpose of this study was to evaluate the efficacy of acupressure at the P6 point for the in-patient treatment of severe nausea and vomiting in early pregnancy. STUDY DESIGN: This was a prospective single-blind randomized control trial that involved 80 patients with nausea and vomiting plus ketonuria before 14 weeks of gestation. RESULTS: There was no difference between length of stay, amount of medication, or fluid required between the acupressure and placebo groups, although acupressure reduced the number of patients who stayed > or =4 nights in the hospital. Acupressure was well tolerated and not associated with an increase in perinatal morbidity or death. CONCLUSION: The use of acupressure at the P6 point does not reduce the amount of antiemetic medication that is required, the requirement for intravenous fluid, and median duration of in-patient stay more than the use of placebo. A small reduction was seen in the number of women who required > or =4 days in the hospital.
Authors: Els Van den Heuvel; Maria Goossens; Hilde Vanderhaegen; Hai Xia Sun; Frank Buntinx Journal: BMC Complement Altern Med Date: 2016-01-13 Impact factor: 3.659